Nimotuzumab
- Generic Name
- Nimotuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 780758-10-3
- Unique Ingredient Identifier
- 6NS400BXKH
- Indication
Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.
- Associated Conditions
- Advanced Head and Neck Cancer, Advanced Stage Head and Neck Cancer, Glioblastoma Multiforme (GBM), High Grade Glioma (HGG), Advanced Epithelial Tumor of the Head and Neck
- Associated Therapies
- -
A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer
- Conditions
- First Posted Date
- 2014-03-24
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- National Institute of Cancerología
- Target Recruit Count
- 15
- Registration Number
- NCT02095119
- Locations
- 🇲🇽
Instituto Nacional de Cancerología, Mexico City, Federal District, Mexico
Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Zhejiang University
- Registration Number
- NCT02041819
- Locations
- 🇨🇳
The first affiliated hospital, Zhejiang University, Zhejiang, Zhejiang, China
Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Zhejiang University
- Registration Number
- NCT02034968
- Locations
- 🇨🇳
The first affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China
Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-12-13
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- Zhejiang University
- Registration Number
- NCT02011594
- Locations
- 🇨🇳
Qiong Zhao, Hangzhou, Zhejiang, China
🇨🇳The first affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China
Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Peking University
- Target Recruit Count
- 9
- Registration Number
- NCT01993784
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2015-06-04
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT01939054
- Locations
- 🇨🇳
Xijing Hospital, Xi-an, Shanxi, China
🇨🇳The General Hospital of the People's Liberation Army (PLAGH), Beijing, Beijing, China
🇨🇳Beijing cancer hospital, Beijing, Beijing, China
Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-07-15
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT01899118
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2018-03-26
- Lead Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT01813253
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇰🇷Hwansun Junnam hospital, Gwangju, Korea, Republic of
Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Clinical Trial
- First Posted Date
- 2011-11-02
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 46
- Registration Number
- NCT01463605
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers
- Conditions
- Interventions
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- Dr. Te Vuong
- Target Recruit Count
- 1
- Registration Number
- NCT01382745
- Locations
- 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.